AEterna Zentaris (AEZS) Shares are Up 1.09%

AEterna Zentaris (AEZS) : Traders are bullish on AEterna Zentaris (AEZS) as it has outperformed the S&P 500 by a wide margin of 10.62% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.75%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.09% in the last 1 week, and is up 10.39% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 4.58% and the fifty day Moving Average is 7.25%. Aeterna Zentaris Inc. is up 6.29% in the last three month period. Year-to-Date the stock performance stands at -16.96%.

AEterna Zentaris (AEZS) : Currently there are 4 street experts covering AEterna Zentaris (AEZS) stock. The most bullish and bearish price target for the stock is $12 and $10 respectively for the short term. The average price target of all the analysts comes to $11. The estimated standard deviation from the target is $0.82.


AEterna Zentaris (NASDAQ:AEZS): stock turned positive on Friday. Though the stock opened at $3.66, the bulls momentum made the stock top out at $3.74 level for the day. The stock recorded a low of $3.63 and closed the trading day at $3.72, in the green by 2.76%. The total traded volume for the day was 68,110. The stock had closed at $3.62 in the previous days trading.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *